Clinical trial · Observational
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Novel Biomarkers for Evaluation of Hemostasis and Inflammation in Liver Cirrhosis
NCT06212635CI-TRIAL-00073116HELICSrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemostasis in Decompensated Liver Cirrhosis | — | UNRESOLVED | — |
| Inflammation in Decompensated Liver Cirrhosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| T-TAS | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Non-acute decompensated liver círrhosis
- description
- Refractory ascites, low grade encephalopathy but manages to stay at home and only come in ofr check-ups.
- interventionNames
- Diagnostic Test: T-TAS
- label
- Acute decompensated liver cirrhosis
- description
- Acute event causing further decompensation and the need for in-patient care
- interventionNames
- Diagnostic Test: T-TAS
- label
- Acute on chronic liver failure
- description
- ACLF 1-3 accordic to criterias established through the Cannonic study.
- interventionNames
- Diagnostic Test: T-TAS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with decompensated liver cirrhosis * 18 years or older. * Healthy individuals 18 years or older will serve as controls. Exclusion Criteria: * • Extrahepatic malignancy or recurrence of such within the last year. * Diagnosis of non-cirrhotic coagulopathy, coagulation disorder or thrombophilia prior to inclusion. * Diagnosis of hematological disease such as hematologic malignancies, non-cirrhotic thrombocytopenia or thrombocytosis, Polycytemia Vera, hemoglobinopathies * Previous liver transplantation. * Transfusions the last 7 days. * Treatment with platelet inhibitors or anticoagulant except for prophylactic dosage of LMWH. If a prophylactic dose of LMWH has been used study sampling with addition of antiFXa must be taken \>12 hours after the last injection.
References
Publications (0)
Data not yet available
No reference posted for this study.